NGEN Company Profile and Key Details

NervGen Pharma Corp. Common stock generated EPS of -$0.26 over the past year. Five-year average earnings growth is 1.73%. Wall Street analysts project EPS growth of 1.68% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $18.00 to $18.00. The high target offers 867.74% upside. The low target suggests 867.74% downside. The mean target is $18.00. This offers 867.74% upside. NervGen Pharma Corp. Common stock earnings surprise history is a mixed track record. The quarter that ended May 18, 2026, missed forecasts by -11.55%. The prior quarter beat by 125.77%. Over the last six quarters, Apple has recorded several small beats. These include 125.77% in March 31, 2026.

Short-term trend indicators are mixed aligned (SMA20 1.03%, SMA50 -12.15%, SMA200 26.11%). The stock’s 14-day RSI is 44.32 (neutral), while the ATR of 0.29 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -33.65% below its high and over 178.67% above its low. Average 10-day trading volume of 736.51 thousand shares is below the 3-month average of 832.72 thousand, indicating normal recent market interest.

NervGen Pharma Corp. Common stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.21. This means the shares are trading above this model’s fair value.

currently trading near 52-week highs band. Valuation shows NervGen Pharma Corp. Common stock trading at a premium to the broader market with a P/E of -4.11. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $18.00, suggesting 867.74% upside. Our AI forecast model points to short-term weakness (-17.2% over two weeks), a medium-term fall (-62.37% over three months), and a longer-term loss (-91.4% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that NervGen Pharma Corp. Common stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -17.2%, with price expected at $1.54 by July 22, 2026, within a range of $0.94 to $2.21 3-Month Outlook: Projected fall of -62.37%, reaching $0.70 by October 06, 2026, with a range of $0.62 to $0.76. 1-Year Outlook: Projected loss of -91.4%, with price at $0.16 by July 08, 2027, within a range of $0.09 to $0.20.

NervGen Pharma Corp. Common stock (NASDAQ:NGEN) closed at $1.86 USD, gaining $0.01 (0.54%) from the previous close of $1.85. The stock is currently mid-range between its 52-week high and low $1.70 and $6.30. With a market capitalization of about $152.88 million, NervGen Pharma Corp. Common stock is classified as a micro-cap and shows lower-than-market volatility (beta ~0.69). Key stats such as the average daily volume over the past year has been around 816.02 thousand shares, in line with its 52-week average. Headquartered in West Vancouver, BC, NervGen Pharma Corp. Common stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Adam H. Rogers, the company employs approximately 7 people and listed since February 08, 2021. NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases.

NervGen Pharma Corp. Common stock trades at a P/E ratio of -4.11, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 38.43 reflecting a rich premium to book value. The P/FCF stands at -7.97, also above market averages. Compared to sector medians, NervGen Pharma Corp. Common stock P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.